Related Experiment Videos
Pharmacokinetics and clinical aspects of azlocillin in paediatrics
Insights
Azlocillin is effective for treating Pseudomonas infections in newborn infants. Dosing of 100-200 mg/kg/day ensures therapeutic levels without accumulation.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Pseudomonas infections pose significant risks to newborn infants.
- Effective antibiotic treatment is crucial for neonatal outcomes.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of azlocillin in neonates with Pseudomonas infections.
- To determine optimal azlocillin dosing for achieving therapeutic serum concentrations.
Main Methods:
- A pharmacokinetic and clinical study was conducted in 25 neonates.
- Azlocillin was administered intravenously at a dose of 50 mg/kg.
- Concentration-time data were analyzed using a two-compartment model.
Main Results:
- Azlocillin exhibited rapid diffusion between central and peripheral compartments.
- The elimination half-life was 2.5-2.6 hours, with no significant differences between premature and mature neonates.
- A daily dose of 100-200 mg/kg is recommended to maintain serum concentrations of 50-80 mg/l.
Conclusions:
- Azlocillin demonstrates favorable pharmacokinetic properties and clinical efficacy in treating neonatal Pseudomonas infections.
- The recommended dosage prevents non-linear kinetics and drug accumulation.
- Azlocillin is a viable option for neonatal Pseudomonas-related infections, including bronchopulmonary and local infections.
Abstract:
A pharmacokinetic and clinical study was done in 25 newborn infants suffering predominantly from pseudomonas infections treated with azlocillin. After a single iv dose of 50 mg azlocillin per kg bodyweight in biphasic concentration time course suggested an open two compartment body model. There was a rapid diffusion between the peripheral and the central compartment. The elimination half life calculated from the beta-slope was 2.5-2.6 h, and differences between premature neonates with more than 2000 g body weight and mature neonates were absent. To maintain a median steady state concentration of 50-80 mg/l in the serum 100-200 mg azlocillin/kg body weight per day must be given. Using this dosage non-linear kinetics and an accumulation of the drug would not occur. Bacteriological and clinical results confirm that in neonatal reinfection, and bronchopulmonary and local infection caused by pseudomonas strains, azlocillin has favourable properties.